• Estimating the 5-year and lifetime risk of developing invasive breast cancer in women aged 35 years and older.
• Determining eligibility for prophylactic breast cancer risk-reducing medications (Tamoxifen/Raloxifene).
• Triaging patients for enhanced screening protocols (e.g., adjunctive Breast MRI).

• Current Age of the patient.
• Age at menarche (earlier is higher estrogen exposure risk).
• Age at the time of first live birth (or nulliparity; older age is higher risk).
• Number of first-degree female relatives (mother, sister, daughter) with breast cancer.
• Number of previous benign breast biopsies.
• Presence of Atypical Hyperplasia explicitly confirmed on a prior biopsy.

• The Gail Model only considers FIRST-degree relatives. It entirely ignores paternal history, second-degree relatives, and the age of onset of cancer in those relatives.
• Calculates the risk of INVASIVE breast cancer only, completely stripping out the risk for developing non-invasive in-situ ductal disease.
• African American and Hispanic populations historically had their risks underestimated until subsequent mathematical calibrations were added; always utilize an ethnicity-adjusted version if available.

• If 5-Year risk exceeds 1.67%, initiate a shared-decision making discussion regarding SERMs (Selective Estrogen Receptor Modulators).
• Premenopausal High Risk: Consider Tamoxifen for 5 years.
• Postmenopausal High Risk: Consider Tamoxifen, Raloxifene, or Aromatase Inhibitors.
• Caution: SERMs significantly increase the risk of deep vein thrombosis (DVT/PE) and endometrial cancer. Baseline absolute risk must outweigh these side-effects.

Dr. Mitchell Gail introduced this algorithm to specifically help clinical trial managers identify high-risk women who were mathematically optimal for inclusion in the landmark Breast Cancer Prevention Trial (BCPT), ensuring enough statistical power could be reached.